Introduction
============

Micafungin (MICA) is an efficacious antifungal treatment for life-threatening fungal infections \[[@B1]-[@B4]\].

Methods
=======

We characterised the safety of MICA by analysing pooled adverse event (AE) data from 17 clinical studies conducted worldwide. All patients (*n*= 3,028) received ≥ 1 dose of intravenous MICA; a median daily dose of 100 mg for adults and 1.5 mg/kg for children over a mean duration of 18 and 29 days, respectively.

Results
=======

Median age was 40.5 (range \<0.1--92) years, including 296 (9.8%) children (\<16 years old) and 387 (12.8%) elderly patients (≥ 65 years old). Common underlying conditions were haematopoietic stem cell or other transplantation (26%), malignancies (21%) and HIV (33%). The most frequently reported MICA-related AEs were nausea (2.8%), vomiting (2.5%), phlebitis (2.5%), hypokalaemia (2.1%), pyrexia (2.1%), diarrhoea (2.0%), and increases in alkaline phosphatase (2.7%), aspartate aminotransferase (2.3%) and alanine aminotransferase (2.0%). In comparative studies, the MICA safety profile was superior to liposomal amphotericin B, and similar to fluconazole and caspofungin (Figure [1](#F1){ref-type="fig"}).
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Conclusion
==========

This large database with more than 3,000 patients demonstrated a favourable clinical safety profile for micafungin.
